123
Participants
Start Date
March 2, 2021
Primary Completion Date
September 20, 2023
Study Completion Date
August 27, 2025
Atezolizumab
Atezolizumab at a fixed dose of 1200 mg will be administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
Tiragolumab
Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Placebo
Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
China Medical University Hospital, Taichung
Auckland City Hospital, Cancer and Blood Research, Auckland
Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont, Kecskemét
Pécsi Tudományegyetem, Pécs
Gy?r-Moson-Sopron Vármegyei Petz Aladár Egyetemi Oktató Kórház, Gy?r
National Taiwan University Hospital, Zhongzheng Dist.
Ramathibodi Hospital, Bangkok
Attiko Hospital University of Athens, Athens
Centre Francois Baclesse, Caen
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Johns Hopkins Hospital, Baltimore
Asst Degli Spedali Civili Di Brescia, Brescia
SCRI Florida Cancer Specialists PAN, Tallahassee
CHU Bordeaux, Bordeaux
Institut régional du Cancer Montpellier, Montpellier
Tennessee Oncology - Nashville, Nashville
Hospital Universitari i Politecnic La Fe, Valencia
Azienda Ospedaliero-Universitaria Careggi, Florence
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy
Washington University School of Medicine, St Louis
Centre Leon Berard, Lyon
Institut Curie, Paris
MD Anderson Cancer Center, Houston
UCLA, Los Angeles
Songklanagarind Hospital, Songkhla
Moores Cancer Center at UC San Diego Health, La Jolla
Taipei Veterans General Hospital, Taipei
Masarykuv onkologicky ustav, Brno
Fakultni nemocnice Hradec Kralove, Hradec Králové
Fakultni nemocnice v Motole, Prague
Anticancer Hospital Ag Savas, Athens
Periph. University General Hospital of Heraklion Crete, Heraklion
Euromedical General Clinic of Thessaloniki, Thessaloniki
Beskidzkie Centrum Onkologii- Szpital Miejski, Bielsko-Biala
Uniwersyteckie Centrum Kliniczne, Gda?sk
Centrum Terapii Wspolczesnej J.M.Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz
Centrum Onkologii Ziemi Lubelskiej Im. ?W. Jana Z Dukli, Lublin
Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Hospital Universitari Germans Trias i Pujol, Badalona
Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona
Velindre Cancer Centre, Cardiff
Beatson West of Scotland Cancer Centre, Glasgow
Guys and St Thomas NHS Foundation Trust, Guys Hospital, London
Royal Marsden NHS Foundation Trust, Sutton
Hoffmann-La Roche
INDUSTRY